CA2347847A1 - Technique de traitement de la tumeur utilisant l'apoptose induite par le fas - Google Patents

Technique de traitement de la tumeur utilisant l'apoptose induite par le fas Download PDF

Info

Publication number
CA2347847A1
CA2347847A1 CA002347847A CA2347847A CA2347847A1 CA 2347847 A1 CA2347847 A1 CA 2347847A1 CA 002347847 A CA002347847 A CA 002347847A CA 2347847 A CA2347847 A CA 2347847A CA 2347847 A1 CA2347847 A1 CA 2347847A1
Authority
CA
Canada
Prior art keywords
vector
cells
promoter
protein
specific promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002347847A
Other languages
English (en)
Inventor
Jian-Yun Dong
James S. Norris
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MUSC Foundation for Research Development
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2347847A1 publication Critical patent/CA2347847A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
    • C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une technique de destruction des cellules tumorales Fas?+¿, consistant à introduire dans une seconde cellule tumorale des acides nucléiques codant le ligand Fas (FasL). La seconde cellule tumorale exprime les acides nucléiques produisant ainsi le FasL et l'interaction de la cellule tumorale Fas?+¿ avec la seconde cellule tumorale exprimant FasL déclenche l'apoptose de la cellule tumorale Fas?+¿, détruisant ainsi cette cellule.
CA002347847A 1998-11-06 1999-11-05 Technique de traitement de la tumeur utilisant l'apoptose induite par le fas Abandoned CA2347847A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10736398P 1998-11-06 1998-11-06
US60/107,363 1998-11-06
PCT/US1999/026221 WO2000027883A2 (fr) 1998-11-06 1999-11-05 Technique de traitement de la tumeur utilisant l'apoptose induite par le fas

Publications (1)

Publication Number Publication Date
CA2347847A1 true CA2347847A1 (fr) 2000-05-18

Family

ID=22316259

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002347847A Abandoned CA2347847A1 (fr) 1998-11-06 1999-11-05 Technique de traitement de la tumeur utilisant l'apoptose induite par le fas

Country Status (5)

Country Link
EP (1) EP1127075A2 (fr)
JP (1) JP2002529068A (fr)
AU (1) AU1344200A (fr)
CA (1) CA2347847A1 (fr)
WO (1) WO2000027883A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2585645C (fr) 2004-10-29 2014-10-21 Musc Foundation For Research Development Ceramides et ligands de signalisation de l'apoptose
EP1814854B1 (fr) 2004-10-29 2015-02-25 MUSC Foundation For Research Development Ceramides cationiques et leurs analogues, et leur utilisation pour la prevention ou le traitement du cancer
CN102368905B (zh) 2008-11-06 2015-04-01 南卡罗来纳医科大学研究发展基金会 酸性神经酰胺酶的向溶酶体抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046310A (en) * 1996-03-13 2000-04-04 Protein Design Labs., Inc. FAS ligand fusion proteins and their uses
WO1998037185A2 (fr) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vecteurs pour expression genique regulee

Also Published As

Publication number Publication date
JP2002529068A (ja) 2002-09-10
AU1344200A (en) 2000-05-29
EP1127075A2 (fr) 2001-08-29
WO2000027883A2 (fr) 2000-05-18
WO2000027883A3 (fr) 2000-07-27
WO2000027883B1 (fr) 2000-09-14

Similar Documents

Publication Publication Date Title
US5932210A (en) Recombinant adenoviral vector and methods of use
CA2173975C (fr) Vecteur recombinant d'adenovirus et procedes d'utilisation
EP1032696B1 (fr) Vecteur pour replication et expression genique a specificite tissulaire
CA2206179C (fr) Vecteurs de replication a specificite tissulaire
US7041284B2 (en) Recombinant adenoviral vector and method of use
WO1998035028A9 (fr) Systeme de vecteurs adenoviraux complementaires oncolytiques/immunogenes
CA2280237A1 (fr) Systeme de vecteurs adenoviraux complementaires oncolytiques/immunogenes
WO2005107474A2 (fr) Adenovirus oncolytique a genes therapeutiques
JP4350800B2 (ja) 高キャパシティーアデノウイルスベクターの開発の促進に使用するためのパッケージング細胞系
US20070253932A1 (en) Recombinant adenoviral vectors and methods of use
AU2001290720A1 (en) Method and composition for treating tumors by selective induction of apoptosis
CA2369820A1 (fr) Acides nucleiques codant pour des polypeptides chimeres cd40/cd40l, leurs procedes de production et leurs utilisations
EP1067194A1 (fr) Vecteurs contenant des gènes codant pour CD40 et/ou CD40L, sous le contrôle du promoteur inductibles à cytokine, qui est un promoteur d'amyloide sérique à phase aigue humaine. Procédés de leur fabrication et leurs utilisations
JP2005500247A (ja) ヒトｍｄａ−７に関わる処置方法
US20110178282A1 (en) Methods and compositions for cancer therapy using a novel adenovirus
JP2002543792A (ja) ベクターによるトランスポゾン配列の供給及び組込み
CA2347847A1 (fr) Technique de traitement de la tumeur utilisant l'apoptose induite par le fas
US6900185B1 (en) Method of inducing tumor cell apoptosis using trail/Apo-2 ligand gene transfer
JP2003500422A (ja) 石灰化した腫瘍および組織を治療するためのオステオネクチンに基づく毒性遺伝子治療
KR19990067174A (ko) 암 치료를 위한 지에이엑스 단백질의 용도
AU2004202604A1 (en) A Method of Treating Tumors Using Fas-induced Apoptosis
US7267978B1 (en) Chimeric transcriptional regulatory element compositions and methods for increasing prostate-targeted gene expression
WO2005007109A2 (fr) Procedes et compositions destines a la cancerotherapie et mettant en oeuvre un nouvel adenovirus
Abdeta Review on Gene Therapy of Prostate Cancer
EP1187923A1 (fr) Inhibition de l'apoptose par l'adenovirus e 3/6.7k

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead